Revealing IGHV3OR16-12: a potential immunoglobulin heavy chain target

Target Name: IGHV3OR16-12

NCBI ID: G28304

IGHV3OR16-12

Other Name(s): immunoglobulin heavy variable 3/OR16-12 (non-functional) | Immunoglobulin heavy variable 3/OR16-12 (non-functional) | IGHV3OR1612

Revealing IGHV3OR16-12: a potential immunoglobulin heavy chain target

Summary

Immunoglobulin heavy chain (IGHV3OR16-12) is an important component of the immune system and plays a key role in a variety of immune functions. However, its abnormal expression in certain diseases may lead to adverse consequences. IGHV3OR16-12 is also highly expressed in a variety of tumors. Therefore, studying its role in tumorigenesis and potential drug targets has important clinical significance. This article mainly introduces the structure, function, tumor expression and possibility of being a drug target of IGHV3OR16-12.

1. Structure and function

IGHV3OR16-12 is an immunoglobulin molecule composed of 16 immunoglobulin heavy chain subunits and 12 immunoglobulin light chain subunits. Both its light chain and heavy chain are composed of a single polypeptide chain, including variable region, constant region and J chain at the end of the heavy chain. The heavy chain of IGHV3OR16-12 includes five subregions 伪, 尾, 纬, 未 and 蔚, while the light chain includes four subregions 伪, 尾, 纬 and 未.

1. Structural characteristics

The heavy chain of IGHV3OR16-12 consists of 564 amino acids, and the light chain consists of 516 amino acids. The combination between the two subregions is composed of a long variable region (Variable Region, V) and a short constant region (C constant region). V consists of an N-terminal 伪-helix, a central 尾-sheet, and a C-terminal 尾-helix. The C constant region consists of an N-terminal 伪-helix, a central 尾-sheet, and a C-terminal 伪-helix. In addition, the heavy chain of IGHV3OR16-12 also has a short J chain, consisting of 14 amino acids.

2. Functional analysis

IGHV3OR16-12 plays an important role in a variety of physiological and pathological processes. In the immune response, the heavy chain of IGHV3OR16-12 specifically binds to the immunoglobulin light chain, initiating the activation and proliferation of B cells and T cells. In tumorigenesis, abnormal expression of IGHV3OR16-12 may lead to immune escape of tumor cells, thereby increasing tumor sensitivity to immunotherapy.

3. Tumor expression

IGHV3OR16-12 is expressed in a variety of tumors, including lung cancer, liver cancer, breast cancer, and kidney cancer. Studies have shown that the expression level of IGHV3OR16-12 is positively correlated with tumor invasiveness and growth rate. In addition, the expression level of IGHV3OR16-12 is also related to the survival rate of tumor patients. Therefore, studying IGHV3OR16-12 as a tumor treatment target has important clinical value.

2. Possibility as a drug target

1. Drug targets

IGHV3OR16-12, as a functional immunoglobulin heavy chain molecule, can be used as a drug target. At present, drug research on IGHV3OR16-12 mainly focuses on regulating its expression level in tumor cells and promoting its degradation in tumor cells.

2. Regulate expression levels

(1) Small RNA (SmRNA): By binding to the heavy chain variable region of IGHV3OR16-12, some small RNAs (such as miRNA) can target the expression of the heavy chain of IGHV3OR16-12. These miRNAs may include anti-tumor miRNAs, such as miR-18a, miR-30a, miR-196, etc.

(2) Peptides: Peptides produced by some tumor cells, such as peptide vaccines, may stimulate tumor cells to express IGHV3OR16-12 by binding to the heavy chain of IGHV3OR16-12, thus evading immune surveillance and increasing tumor growth rate.

3. Promote degradation

(1) Anti-tumor drugs: Some anti-tumor drugs, such as anti-angiogenic drugs, anti-tumor antibiotics and topoisomerase inhibitors, can act on IGHV3OR16-12 in various ways to promote its degradation in tumor cells. thereby inhibiting tumor growth.

(2) Extracellular vesicles (Exosome): Extracellular vesicles produced by tumor cells, which may contain particles such as anti-tumor drugs, can promote their expression in tumor cells by being released outside the cell and binding to the heavy chain of IGHV3OR16-12 degradation.

3. Summary

IGHV3OR16-12 is a potential immunoglobulin heavy chain target. Studying its structure, function and tumor expression can reveal its role in tumorigenesis and provide new targets and strategies for tumor immunotherapy. At present, drug research on IGHV3OR16-12 mainly focuses on regulating its expression level in tumor cells and promoting its degradation in tumor cells. With the deepening of research, it is expected to bring better therapeutic effects to tumor patients in the future.

Protein Name: Immunoglobulin Heavy Variable 3/OR16-12 (non-functional)

The "IGHV3OR16-12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV3OR16-12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets